GLP-1 Clinical Practice Updates: April 2026 Key Developments

May 1, 2026

April brought several developments worth tracking in the GLP-1 landscape. New clinical data continued to add to what providers know about patient selection, long-term adherence, and the expanding list of conditions GLP-1s appear to address. On the regulatory side, the FDA followed up on the newly approved oral GLP-1 Foundayo with a post-marketing safety request, and the Medicare coverage program announced in December underwent a structural change before it even launched.

This update covers what changed and what it means for your practice.

In this GLP-1 round up:

GLP-1 Adherence: Preclinical data suggesting that cycling on and off GLP-1s may reduce their long-term effectiveness — and what to tell patients now.
GLP-1 Patient Selection: How to access and use OBScore, a free new tool that predicts risk across 18 obesity-related complications.
Medicare Bridge Program: How the structure of the $50 copay program changed, and the specific clinical criteria your patients must meet before the July 1 launch.
Expanding GLP-1 Benefits: New data on atrial fibrillation, alcohol use disorder, depression, and vascular complications in diabetic retinopathy.

Clinical Practice — Adherence & Patient Management

The Stop-Start Problem: Cycling Off GLP-1s May Reduce Effectiveness

A relatable scenario for many practices is the patient who stops and starts GLP-1 therapy due to cost, insurance gaps, or seasonal use. New preclinical data from Penn Medicine suggests that intermittently stopping and restarting GLP-1s may cause therapeutic resistance.

The researchers found the effect may be tied to changes in body composition that occur during the off-cycle period. While this is a preclinical study and human confirmation is needed, it provides a biological rationale for what many providers observe clinically. Action Item: Counsel patients that GLP-1s appear to work best with consistent, long-term use. Proactively address barriers to adherence — including cost and insurance gaps — before patients discontinue therapy.

A New "Off-Ramp": Duodenal Mucosal Resurfacing After GLP-1 Discontinuation

For patients who do need to stop GLP-1 therapy, finding an effective “off-ramp” to prevent weight regain is a major clinical challenge. A new investigational approach called Duodenal Mucosal Resurfacing (DMR) is showing early promise. DMR is an outpatient endoscopic procedure that uses controlled heat to resurface the inner lining of the duodenum — the first section of the small intestine. This essentially “resets” the gut’s metabolic signaling.

The duodenum plays a critical role in metabolic hormone signaling. In people with obesity, this lining can become dysfunctional. By ablating and regenerating it, DMR appears to restore more normal metabolic responses. The procedure takes approximately 60 minutes, requires no incisions, and is performed under sedation.

According to data from the REMAIN-1 trial presented at Digestive Disease Week, patients who underwent DMR after stopping tirzepatide maintained over 80% of their weight loss at 6 months. Meanwhile, the sham group regained 40% more weight.

The device (Revita by Fractyl Health) holds FDA Breakthrough Device Designation for weight loss maintenance. It is not yet commercially available in the U.S. The pivotal cohort’s 6-month primary endpoint data is expected later in 2026.

This is a “watch this space” development. It is not something providers can currently offer patients, but it is highly relevant to the broader conversation about long-term weight management.

OBScore: A Free Tool for Better GLP-1 Patient Selection

A new free web-based tool called the OBScore Risk Calculator is now available to help providers make a more individualized case for GLP-1 therapy. Developed by researchers at Queen Mary University of London and reported on by STAT News, the tool uses 20 clinical variables to predict risk for 18 obesity-related complications.

This goes beyond BMI to assess a patient’s true comorbidity burden. The tool is freely accessible here with no login required.

Action Item: Use OBScore to have a more nuanced conversation with patients about why GLP-1 treatment is being recommended. This is particularly useful for those who may not meet traditional BMI thresholds but carry significant risk across multiple conditions.

OBScore is a research-based decision-support tool and is not a certified diagnostic instrument. Results should be interpreted alongside clinical judgment and are not a substitute for a comprehensive patient evaluation. If used in a research or publication context, the tool’s developers require citation of the underlying study.

Quick Update — Lean Muscle Mass: A Continuing Conversation

A new preprint study (not yet peer-reviewed) suggests that tirzepatide may cause slightly more relative lean body mass loss than semaglutide. This adds nuance to the ongoing debate we covered in our March 2026 update. The core action item for providers remains unchanged: continue prescribing resistance training and adequate protein intake for all patients on GLP-1 therapy. Given the preprint status of this data, providers should await peer review before adjusting clinical protocols.

Regulatory & Policy Updates

Foundayo Follow-Up: FDA Requests Post-Marketing Safety Data

Following the approval of Foundayo (orforglipron) — the first oral non-peptide GLP-1 receptor agonist without food or water restrictions — the FDA quickly issued a post-marketing safety request to Eli Lilly. They asked for additional studies to monitor potential liver injury and cardiovascular risks.

The FDA’s post-marketing safety letter was dated April 1, 2026. However, on April 16, Eli Lilly announced topline results from the Phase 3 ACHIEVE-4 trial. This trial showed a 16% lower risk of major adverse cardiovascular events (MACE-4) compared to insulin glargine.

While this subsequent data provides some reassurance, the FDA is maintaining a cautious approach with this new class of oral agents.

Action Item: Providers prescribing Foundayo should monitor patients for liver function abnormalities. Stay alert for potential label updates as post-marketing data emerges. For a detailed clinical comparison of this new agent, read our breakdown: Oral GLP-1: Foundayo vs. Wegovy Pill.

Medicare GLP-1 Bridge: What Actually Changed

In our March 2026 update, we advised providers to prepare for the BALANCE model launching July 1, 2026. The Part D insurer-based component of BALANCE was subsequently canceled following pushback from insurers over the financial strain of the model, as reported by STAT News.

The government will now fund the program directly, outside standard Part D. This is according to the CMS Medicare GLP-1 Bridge resource page.

The program structure changed, but the patient access outcome — a $50 copay for eligible Medicare beneficiaries — remains the goal. The July 1, 2026 launch date is still on track. Eligible medications include Foundayo, Wegovy, and the Zepbound KwikPen, and the program runs through December 31, 2027.

Who is eligible?

The program is available nationwide. To qualify, a Medicare beneficiary must be enrolled in a standalone Part D prescription drug plan (PDP) or a Medicare Advantage plan with drug coverage (MA-PD) in 2026. Clinical eligibility requires one of the following:

Medicare GLP-1 Bridge: Clinical Eligibility Criteria

Source: Centers for Medicare & Medicaid Services — effective July 1, 2026.

Medicare GLP-1 Bridge clinical eligibility tiers — CMS, 2026
Eligibility Tier	BMI Threshold	Additional Criteria Required
Tier 1	BMI ≥ 35	None
Tier 2	BMI ≥ 30	Heart failure with preserved ejection fraction, uncontrolled hypertension (systolic >140 or diastolic >90 on two antihypertensives), or CKD stage 3a or above
Tier 3	BMI ≥ 27	Pre-diabetes, previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease

To access the program, a provider submits a prior authorization request along with a prescription. Providers do not need to be enrolled in Medicare to submit a prior authorization request. The prior authorization process will be managed through a single central processor designated by CMS. Details on that processor are expected from CMS in Spring 2026.

Action Item: Identify Medicare Part D patients in your practice who meet these criteria now, before the July 1 launch. The official CMS resource page for providers is available here.

Medicaid Coverage: The Patchwork Grows

The landscape for Medicaid coverage of GLP-1s continues to fragment. Following moves by California, New Hampshire, Pennsylvania, and South Carolina to drop GLP-1 coverage for weight loss, Massachusetts and Rhode Island are now considering similar restrictions.

Patients on Medicaid in these states will increasingly need alternative pathways. This makes manufacturer assistance programs and direct-pay options more critical.

Regulatory Notes

On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List, according to the FDA press announcement. Both drugs had already been removed from the FDA’s shortage list in early 2025, which ended the primary legal basis for bulk compounding. This proposal closes the remaining non-shortage pathway and formalizes what enforcement actions have made clear over the past year. The public comment period is open until June 29, 2026.

Other Emerging Benefits from GLP-1s

Atrial Fibrillation Risk Reduced — Even Without Weight Loss

A retrospective study of 13,034 patients presented at Heart Rhythm 2026 found that GLP-1 use was associated with a reduced risk of atrial fibrillation.

The study found a hazard ratio of 0.75 (95% CI, 0.64–0.88), representing a 25% relative risk reduction. Crucially, this benefit held even in patients who gained weight on GLP-1 therapy. This suggests an independent anti-inflammatory or pericardial fat mechanism rather than a weight-mediated one.

Semaglutide + CBT Reduces Heavy Drinking in Alcohol Use Disorder

A randomized controlled trial published in The Lancet found that semaglutide combined with cognitive behavioral therapy (CBT) resulted in a 41.1% reduction in heavy drinking days. This was among patients with alcohol use disorder (AUD) and obesity.

The number needed to treat (NNT) was 4.3, which compares favorably to currently approved AUD medications. The NIH’s National Institute on Alcohol Abuse and Alcoholism commented positively on the findings.

The FDA approval pathway for this indication is not yet established, and the trial population had both obesity and AUD. This is not a general population finding.

Oral Semaglutide Improved Motivation in Major Depressive Disorder

A secondary analysis reported by MedPage Today found that among 72 patients with major depressive disorder (MDD) and obesity, oral semaglutide 14 mg improved motivation measures. This was independent of changes in depression severity.

This early-stage finding adds to the growing picture of GLP-1s influencing reward and motivational brain pathways. Larger trials are needed before any clinical conclusions can be drawn.

Vascular Benefits in Diabetic Retinopathy

Research published in the American Journal of Ophthalmology associated GLP-1 agonist use with a reduced risk of major macrovascular and microvascular events in patients with type 2 diabetes and pre-existing diabetic retinopathy.

The retrospective cohort study of over 173,000 patients found that those on GLP-1 therapy experienced several significant reductions compared to matched controls:

35% lower risk of myocardial infarctions
32% lower rate of acute kidney injury
30% lower rate of retinal vein occlusions
24% lower rate of lower extremity amputations
22% lower risk of ischemic strokes

This finding contrasts with ongoing discussions regarding non-arteritic anterior ischemic optic neuropathy (NAION). It provides an important distinction for providers discussing the full ocular risk-benefit picture with patients.

Key Takeaways for Providers

Preclinical data suggests that cycling on and off GLP-1s may lead to therapeutic resistance, underscoring the importance of consistent adherence and proactive barrier management.
Emerging tools like the free OBScore Risk Calculator and investigational procedures like Duodenal Mucosal Resurfacing (DMR) are expanding how providers approach GLP-1 patient selection and long-term weight maintenance.
The Medicare GLP-1 Bridge program launches July 1, 2026, offering a $50 copay for eligible beneficiaries, funded directly by the government rather than through Part D insurers. Providers should identify eligible patients now.
Clinical data continues to highlight the broad systemic benefits of GLP-1s, including reductions in atrial fibrillation risk, heavy drinking days, and vascular complications in diabetic retinopathy.
The FDA’s April 30 proposal to exclude three GLP-1s from the 503B Bulks List formalizes the regulatory direction that has been clear since early 2025. Providers still navigating compounding should plan for a branded-only landscape.

Conclusion

April 2026 continued to demonstrate that GLP-1 medicine is expanding well beyond weight loss. New data on atrial fibrillation, alcohol use disorder, depression, and diabetic retinopathy reinforces that providers who understand the full clinical picture of these medications are better positioned to serve their patients — and to make the case for treatment when coverage barriers arise. At the same time, the regulatory environment is settling into a clearer shape: compounding is winding down, Medicare access is opening up, and the tools available for patient selection are becoming more sophisticated. For practices that have built programs around comprehensive clinical care rather than medication price alone, the landscape ahead looks more favorable than it did a year ago.

The IAPAM’s Certified Medical Weight Management Provider™ (CWMP) program equips you with the protocols, patient-care strategies, and business tools to implement today’s GLP-1 and metabolic therapies effectively. You’ll learn how to integrate medications like tirzepatide, semaglutide, and Saxenda® into a holistic, sustainable program that prioritizes long-term outcomes.

Stay ahead of the science. Strengthen your systems. Empower your patients to succeed.

Explore the program and get the tools you need to build a sustainable, patient-first weight loss practice.

Frequently Asked Questions (FAQs)

What is the Medicare GLP-1 Bridge program?

It is a government-funded program launching July 1, 2026. It provides eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs — Foundayo, Wegovy, and the Zepbound KwikPen — for a $50 monthly copay through December 31, 2027. It replaced the previously announced insurer-based BALANCE model after pushback from Part D insurers over the financial strain of the model.

Who is eligible for the Medicare GLP-1 Bridge?

Beneficiaries must be enrolled in a standalone Part D plan or Medicare Advantage plan with drug coverage. Clinical eligibility requires a BMI ≥35, or a BMI ≥30 with specific comorbidities (heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a or above), or a BMI ≥27 with pre-diabetes, prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease.

What does the FDA’s proposed 503B exclusion mean for compounded GLP-1s?

The proposal closes the last remaining non-shortage pathway for bulk compounding of semaglutide, tirzepatide, and liraglutide. The shortage exception pathway was already closed when both drugs were removed from the FDA shortage list in early 2025. If a new shortage were declared, that exception could theoretically apply again. The comment period closes June 29, 2026.

Is the OBScore Risk Calculator free to use?

Yes. OBScore is a freely accessible web-based tool that uses 20 clinical variables to predict a patient’s risk for 18 obesity-related complications. It is available at omicscience.org/apps/obscore/ with no login required.

What is Duodenal Mucosal Resurfacing (DMR)?

DMR is an investigational outpatient endoscopic procedure that uses controlled heat to resurface the inner lining of the duodenum. Early data from the REMAIN-1 trial suggests it may help patients maintain GLP-1 weight loss after discontinuing therapy by resetting the gut’s metabolic signaling. It is not yet commercially available in the U.S.

Will the FDA’s compounding proposal affect future GLP-1 drugs?

The current proposal names only semaglutide, tirzepatide, and liraglutide. However, the FDA’s stated rationale — that there is no clinical need for compounding when FDA-approved versions are available — would logically apply to future approved GLP-1 agents as well.

Ready to Transform Your Practice with GLP-1s?

Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss.

Sources

Penn Medicine News. Stopping and restarting GLP-1s may make it less effective. April 2026.
Healio Gastroenterology. Duodenal mucosal resurfacing may offer GLP-1 off-ramp while maintaining weight loss. April 23, 2026.
STAT News. A new tool goes beyond BMI to predict the health risks of obesity. April 30, 2026.
Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge. May 1, 2026.
Stateline. More states consider dropping GLP-1 weight loss drugs from Medicaid. April 30, 2026.
Healio Cardiology. GLP-1 use cuts risk for atrial fibrillation regardless of weight loss. April 23, 2026.
The Lancet. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity. May 2026.
JAMA Psychiatry. Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial. April 29, 2026.
American Journal of Ophthalmology. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Outcomes in Patients with Diabetic Retinopathy. April 19, 2026.
medRxiv. Greater lean-body-mass decline with tirzepatide than semaglutide. April 13, 2026.
U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. April 30, 2026.

Celebrating 20 Years of Training in Botox®, Aesthetic Medicine
and Medical Weight Management

Celebrating 20 Years of Excellence in Botox®, Aesthetic Medicine & Medical Weight Management Training & Certification